HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoefnagel, C. A. Articles by Marcuse, H. R. Search for Related Content PubMed PubMed Citation Articles by Hoefnagel, C. A. Articles by Marcuse, H. R.

Radionuclide Diagnosis and Therapy of Neural Crest Tumors Using Iodine-131 Metaiodobenzylguanidine

Department of Nuclear Medicine and Werkgroep Kindertumoren, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Correspondence: For reprints contact: C. A. Hoefnagel, MD, Dept. of Nuclear Medicine, Antoni van Leeuwenhoekhuis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

ABSTRACT

The successful application of [^13lI]metaiodobenzylguanidine (MIBG) in diagnosis and therapy of pheochromocytoma has led to its use in other tumors which derive from the neural crest and potentially concentrate this radiopharmaceutical as well. In the present series, [¹³¹I]MIBG total-body scintigraphy was used for detection of neuroblastoma in 47 patients and 47 cases of other neural crest tumors. The method was found to be as reliable in neuroblastoma (sensitivity 95%, specificity 100%), as it is in pheochromocytoma. Although other neural crest tumors may concentrate [¹³¹I]MIBG, this is not a consistent finding; however, it is useful to investigate which tumors do, as this may provide an alternative treatment modality for some patients. Although followup is still very short, preliminary results of therapeutic use of [¹³¹I]MIBG in 21 patients indicate that this treatment modality may be effective in neuroblastoma and malignant pheochromocytoma.

This article has been cited by other articles:

				W Mazrani, K McHugh, and P J Marsden The radiation burden of radiological investigations Arch. Dis. Child., December 1, 2007; 92(12): 1127 - 1131. [Abstract] [Full Text] [PDF]

				W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]

				R. J. Mairs, S. C. Ross, A. G. McCluskey, and M. Boyd A Transfectant Mosaic Xenograft Model for Evaluation of Targeted Radiotherapy in Combination with Gene Therapy In Vivo J. Nucl. Med., September 1, 2007; 48(9): 1519 - 1526. [Abstract] [Full Text] [PDF]

				T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert Current Treatment of Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225. [Abstract] [Full Text] [PDF]

				C. K. McGarvey, K. Applegate, N. D. Lee, and D. K. Sokol False-Positive Metaiodobenzylguanidine Scan for Neuroblastoma in a Child With Opsoclonus-Myoclonus Syndrome Treated With Adrenocorticotropic Hormone (ACTH) J Child Neurol, July 1, 2006; 21(7): 606 - 610. [Abstract] [PDF]

				K. K. Matthay, J. C. Tan, J. G. Villablanca, G. A. Yanik, J. Veatch, B. Franc, E. Twomey, B. Horn, C. P. Reynolds, S. Groshen, et al. Phase I Dose Escalation of Iodine-131-Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study J. Clin. Oncol., January 20, 2006; 24(3): 500 - 506. [Abstract] [Full Text] [PDF]

				F. D. Pashankar, M. S. O'Dorisio, and Y. Menda MIBG and Somatostatin Receptor Analogs in Children: Current Concepts on Diagnostic and Therapeutic Use J. Nucl. Med., January 1, 2005; 46(1_suppl): 55S - 61S. [Abstract] [Full Text] [PDF]

				M. M. Ryan and E. C. Engle Topical Review: Acute Ataxia in Childhood J Child Neurol, May 1, 2003; 18(5): 309 - 316. [Abstract] [PDF]

				Y Inoue, M Akahane, T Kitazawa, H Ijichi, S Obi, K Yoshikawa, K Ohtomo, and M Omata False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma Br. J. Radiol., June 1, 2002; 75(894): 548 - 551. [Abstract] [Full Text] [PDF]

				G. A. Yanik, J. E. Levine, K. K. Matthay, J. C. Sisson, B. L. Shulkin, B. Shapiro, D. Hubers, S. Spalding, T. Braun, J. L.M. Ferrara, et al. Pilot Study of Iodine-131-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma J. Clin. Oncol., April 15, 2002; 20(8): 2142 - 2149. [Abstract] [Full Text] [PDF]

				A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]

				R. Zhou, N. Bansal, D. B. Leeper, and J. D. Glickson Intracellular Acidification of Human Melanoma Xenografts by the Respiratory Inhibitor m-Iodobenzylguanidine Plus Hyperglycemia: A 31P Magnetic Resonance Spectroscopy Study Cancer Res., July 1, 2000; 60(13): 3532 - 3536. [Abstract] [Full Text]

				S. Braune, M. Reinhardt, R. Schnitzer, A. Riedel, and C. H. Lucking Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy Neurology, September 1, 1999; 53(5): 1020 - 1020. [Abstract] [Full Text]

				S. Hoegerle, E. Nitzsche, C. Altehoefer, N. Ghanem, T. Manz, I. Brink, M. Reincke, E. Moser, and H. P. H. Neumann Pheochromocytomas: Detection with 18F DOPA Whole-Body PET3Initial Results Radiology, February 1, 2002; 222(2): 507 - 512. [Abstract] [Full Text] [PDF]